Grapefruit Juice-Vinblastine Interaction

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

ALEXANDRIA, Virginia-Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).

ALEXANDRIA, Virginia—Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).

The drugs include vinblastine, cyclosporine (Sandimmune, Neoral), losartan (Cozaar, an antihypertension agent), digoxin, and fexofenadine (Allegra, an antihistamine).

This inhibition occurs, the researchers said, because an unknown substance in grapefruit juice activates one of the body’s naturally produced drug efflux mechanisms, P-glycoprotein, located in the intestinal tract. When grapefruit juice interacts with P-glycoprotein, the result is an increased likelihood that certain drugs will be stopped from entering the bloodstream.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content